Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 8, 2026, 10:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1729–1752 of 6,600 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Glabellar Rhytides
Interventions: Mentor Purified Toxin Botulinum Toxin Type A; Drug
Lead sponsor: Mentor Worldwide, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 576 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Santa Barbara, California

Conditions: Systemic Lupus Erythematosus
Interventions: Abatacept, Placebo, Prednisone; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 12
States / cities: Tucson, Arizona • Long Beach, California • Los Angeles, California + 9 more

Conditions: Sexual Dysfunctions, Psychological, Sexual Arousal Disorder
Interventions: sildenafil; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 267 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2004
U.S. locations: 82
States / cities: Huntsville, Alabama • Anchorage, Alaska • Tucson, Arizona + 68 more

Conditions: Metastatic Breast Cancer, Metastatic Colon/Rectum Cancer, Non-squamous Non-small Cell Lung Cancer
Interventions: [F-18]RGD-K5; Drug
Lead sponsor: Siemens Molecular Imaging; Industry
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 8
States / cities: Irvine, California • Los Angeles, California • Newark, New Jersey + 2 more

Conditions: Nasal Obstruction
Interventions: Vivaer Stylus; Device
Lead sponsor: Aerin Medical; Industry
Eligibility: 22 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 9
States / cities: Fresno, California • Colorado Springs, Colorado • Oradell, New Jersey + 6 more

Conditions: Hepatitis C, Chronic
Interventions: Copegus placebo, RO5024048, danoprevir, peginterferon alfa-2a [Pegasys], ribavirin [Copegus], ritonavir; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 18
States / cities: La Jolla, California • Sacramento, California • Orlando, Florida + 14 more

Conditions: Bone Metastases
Interventions: Bone Scan: F18-Fluoride PET/CT or TC-MDP; Device
Lead sponsor: American College of Radiology - Image Metrix; Industry
Eligibility: 18 Years and older
Enrollment: 550 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2013
U.S. locations: 15
States / cities: Scottsdale, Arizona • Freemont, California • Los Angeles, California + 9 more

Conditions: Glaucoma, Open-angle, Ocular Hypertension
Interventions: 0.01% RO7058584, 0.1% RO7058584, 1% RO7058584, Matching Placebo, Latanoprost 0.005%; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 90 Years
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 8
States / cities: Chandler, Arizona • Artesia, California • Inglewood, California + 5 more

Conditions: Congenital Bleeding Disorder, Congenital FXIII Deficiency
Interventions: catridecacog; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 1 Year to 6 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Boston, Massachusetts • Columbus, Ohio

Conditions: Ulcerative Colitis
Interventions: HMPL-004, Placebo; Drug
Lead sponsor: Hutchison Medipharma Limited; Industry
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Agawam, Massachusetts

Conditions: Breast Cancer
Interventions: Bevacizumab, Standard adjuvant chemotherapy; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 2,591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2014
U.S. locations: 44
States / cities: Huntsville, Alabama • Mobile, Alabama • Fayetteville, Arkansas + 40 more

Conditions: Ovary Cancer, Cervix Cancer, Endometrium Cancer, Bladder Cancer, Prostate Cancer, Esophagus Cancer, Lung Cancer, Nonsmall Cell, Squamous Cell Carcinoma of the Head and Neck
Interventions: Tisotumab Vedotin; Drug
Lead sponsor: Seagen Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Carcinoma, Adenocarcinoma, Renal Cell, Nephroid Carcinoma, Hypernephroid
Interventions: RAD001(everolimus), interferon alfa-2a, bevacizumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 365 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2013
U.S. locations: 9
States / cities: Fayetteville, Arkansas • Duarte, California • Los Angeles, California + 5 more

Conditions: Glioblastoma, GBM
Interventions: 5-ALA HCl + LIDU SDT, Placebo + Sham SDT; Combination Product
Lead sponsor: Alpheus Medical, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 11
States / cities: Boston, Massachusetts • Rochester, Minnesota • Albany, New York + 6 more

Conditions: Acute Myeloid Leukemia
Interventions: RO7283420, Tocilizumab, Dasatinib, Dexamethasone, Paracetamol/acetaminophen, Diphenhydramine; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 2
States / cities: Sacramento, California • Houston, Texas

Conditions: Moderate to Severe Allergic Asthma
Interventions: Not listed
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 6 Years to 11 Years
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2008
U.S. locations: 50
States / cities: Birmingham, Alabama • Crescent City, California • Fresno, California + 47 more

Conditions: Pediatric Procedures, Adult Hepato-pancreato-biliary (HPB) Procedures, Adult Lower Gastrointestinal Procedures, Adult Gastric Procedures, Adult Gynecological Procedures, Adult Urological Procedures, Adult Thoracic Procedures
Interventions: HARMONIC 1100 Shears; Device
Lead sponsor: Ethicon Endo-Surgery; Industry
Eligibility: Not listed
Enrollment: 265 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 4
States / cities: Jacksonville, Florida • Indianapolis, Indiana

Conditions: Insomnia Disorder
Interventions: ACT-541468 5 mg, ACT-541468 10 mg, ACT-541468 25 mg, Zolpidem, Placebo 1, Placebo 2; Drug
Lead sponsor: Idorsia Pharmaceuticals Ltd.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 360 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 15
States / cities: Santa Monica, California • Upland, California • Brandon, Florida + 12 more

Conditions: Erectile Dysfunction
Interventions: AMS 700 IPP with MS Pump; Device
Lead sponsor: American Medical Systems; Industry
Eligibility: 21 Years and older · Male only
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 7
States / cities: Indio, California • New Port Richey, Florida • Shreveport, Louisiana + 4 more

Conditions: Carcinoma, Renal Cell
Interventions: Bay 59-8862; Drug
Lead sponsor: Bayer; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2003
U.S. locations: 13
States / cities: La Jolla, California • Muncie, Indiana • New Orleans, Louisiana + 9 more

Conditions: NMIBC, MIBC, Muscle Invasive Bladder Cancer (MIBC), Non Muscle Invasive Bladder Cancer
Interventions: This is a non-interventional, observational, prospective study.; Other
Lead sponsor: Bladder Cancer Advocacy Network; Other
Eligibility: 18 Years and older
Enrollment: 1,400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Extensive-Stage Small Cell Lung Cancer
Interventions: Carboplatin, Palifosfamide-tris, Etoposide; Drug
Lead sponsor: Alaunos Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 188 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 40
States / cities: Birmingham, Alabama • Los Angeles, California • Santa Rosa, California + 36 more

Conditions: Active Rheumatoid Arthritis
Interventions: Tranilast, Placebo; Drug
Lead sponsor: Nuon Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 9
States / cities: Mesa, Arizona • Paradise Valley, Arizona • La Jolla, California + 6 more

Conditions: Plaque Psoriasis
Interventions: ABT-874, etanercept, placebo; Biological · Drug
Lead sponsor: AbbVie (prior sponsor, Abbott); Industry
Eligibility: 18 Years and older
Enrollment: 347 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 35
States / cities: Tucson, Arizona • Fresno, California • Los Angeles, California + 31 more

Search by objective public record fields.

A Long-Term Safety Study of Repeat Treatment With PurTox® for Frown Lines Between the Eyebrows

Abatacept in the Treatment and Prevention of Active Systemic Lupus Erythematosus (SLE) Flares in Combination With Prednisone

An Open-Label, Extension Study Evaluating the Safety, Toleration, and Efficacy of Sildenafil in Women With Sexual Arousal Disorder

Efficacy Study of [F-18]RGD-K5 Positron Emission Tomography (PET) as a Tool to Monitor Response to an Anti-angiogenic Drug

Treatment of Nasal Airway Obstruction Using the Aerin Medical Device

A Study of RO5024048 in Combination With Ritonavir-Boosted Danoprevir With or Without Copegus (Ribavirin) in Interferon-Naïve Patients With Chronic Hepatitis C Genotype 1 (INFORM-SVR)

F18PET/CT Versus TC-MDP Scanning to Detect Bone Mets

A Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7058584 Following 7 Days of Instillation of Eye Drops in Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency

HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis

BEATRICE Study: A Study of Bevacizumab (Avastin) Adjuvant Therapy in Triple Negative Breast Cancer

Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors.

Safety and Efficacy of Bevacizumab Plus RAD001 Versus Interferon Alfa-2a and Bevacizumab for the First-line Treatment in Adult Patients With Kidney Cancer

Adjuvant Temozolomide ± 5-Aminolevulinic Acid + Low Intensity Diffuse Ultrasound Sonodynamic Therapy System for Newly Diagnosed Glioblastoma

A Dose Escalation and Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7283420.

Observational and Epidemiologic Study of the Disease Course and Unmet Needs in Children With Symptomatic Moderate to Severe Allergic Asthma

A Prospective, Single-Arm Multi-Center Study of the HARMONIC® 1100 Shears in Select Devices

Efficacy and Safety of ACT-541468 in Adult Subjects With Insomnia Disorder

Evaluation of the 2005 AMS (American Medical System) IPP (Inflatable Penile Prosthesis)

Evaluation of Bay 59-8862 in Patients With Advanced Renal Cell Carcinoma

Outcomes for IR and High Risk (HR) Non-muscle Invasive Bladder Cancer (NMIBC) and ctDNA-based Biomarkers for Response and Recurrence in Muscle Invasive Bladder Cancer (MIBC)

Study of Palifosfamide-tris in Combination With Carboplatin and Etoposide in Chemotherapy Naïve Patients With Extensive-Stage Small Cell Lung Cancer (The MATISSE Study)

Safety and Efficacy Study of Tranilast in Patients With Active Rheumatoid Arthritis (RA)

Study Comparing the Efficacy and Safety of ABT-874 to Etanercept and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis